CAM
TGTX icon

Cresset Asset Management’s TG Therapeutics TGTX Stock Holding History

Cresset Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$347K Buy
6,314
+77
+1% +$3.15K ﹤0.01% 1318
2026
Q1 		$207K Sell
6,237
-895
-13% -$26.7K ﹤0.01% 1456
2025
Q4 		$213K Sell
7,132
-2,104
-23% -$68.7K ﹤0.01% 1464
2025
Q3 		$334K Buy
+9,236
New +$304K ﹤0.01% 1198

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Cresset Asset Management's TGTX Position: Q2 2026 in Review

Cresset Asset Management increased its TG Therapeutics (TGTX) stake by 1.2% in Q2 2026, buying an estimated $3.15K and bringing the position to 6,314 shares worth $347K. The position accounts for ﹤0.01% of the portfolio, ranked #1318.

Cresset Asset Management first reported a position in TGTX in Q3 2025 and has held it in 4 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Cresset Asset Management held 6,314 shares of TG Therapeutics worth $347K as of Q2 2026.
  • Cresset Asset Management bought 77 TG Therapeutics shares in Q2 2026, an estimated $3.15K.
  • TG Therapeutics made up ﹤0.01% of Cresset Asset Management's portfolio in Q2 2026, its #1318 holding.
  • Cresset Asset Management first reported a position in TG Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.